Heena Desai

This study evaluates cancer-specific polygenic risk scores (PRS) across diverse ancestries and finds they predict corresponding cancers with varying effectiveness and limited pleiotropy.

This study compares genomic and immunologic features of germline TP53-driven breast cancers to sporadic breast cancers, finding distinct patterns of genomic instability and immune infiltration.

This paper develops a germline polygenic score (PRSagg) to predict prostate cancer aggressiveness and validates it across multiple datasets.

This paper shows the HOXB13 p.G84E variant increases prostate cancer risk by threefold in men, but does not lead to more aggressive cancer.

This study analyzes genomic alterations in metastatic prostate cancer patients across racial groups, finding race-associated differences in mutation frequencies and survival outcomes.

This study identifies 13.9% of neuroblastoma patients with pathogenic germline variants in cancer predisposition genes, associated with worse survival and enriched in DNA repair genes like BARD1.

HRDex calculates HRD scores from whole exome sequencing data to identify BRCA-deficient tumors, showing high accuracy in breast cancer and moderate in ovarian cancer.

This study evaluates polygenic risk scores (PRS) for cancer prediction in a racially diverse biobank, finding moderate improvements in discriminatory accuracy for European ancestry but limited gains for African ancestry.